AmoyDx® Lung Cancer Multi-gene PCR Panel" Receives Additional Approval for Irresectable, Advanced/Recurrent Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation, for Use with Rybrevant® or Livribif® in Combination with Chemotherapy
NQ Score
87/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Riken Genesis Co., Ltd. announced on April 28, 2026, that its in vitro diagnostic "AmoyDx® Lung Cancer Multi-gene PCR Panel" received partial change approval for manufacturing and marketing. This allows its use as a companion diagnostic for specific combination therapies (Rybrevant® or Livribif® with chemotherapy) for non-small cell lung cancer patients with EGFR exon 20 insertion mutations, expanding treatment options.